Elan reported a 42 per cent fall in first quarter revenue today but added that its recovery plan remained on track with strong sales growth from its existing products.
The struggling pharmaceutical company said reported revenue of $260 million compared to $446.6 million in the first quarter of 2002.
But revenue from retained products was $148.8 million in the first quarter of 2003 compared to $104.1 million last year reflecting the growth in prescription sales.
Commenting on the results and recovery plan Mr Kelly Martin, Elan's president and chief executive officer, said the company remained on course with its 18-month recovery plan.
At March 31st, 2003, Elan had $983.6 million in cash which Elan believes is sufficient to meet its current liquidity requirements.
Mr Martin said "While there is much to be done, we remain focused on executing our goals of simplifying Elan's balance sheet, streamlining our operational model and advancing our science and product development."